ClinicalTrials.gg
CompletedNCT00818662Updated May 19, 2021Results posted

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease

A Phase 3 interventional study of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg and Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg in Alzheimer´s Disease, sponsored by Baxalta now part of Shire. Completed at 41 sites in 2 countries. Open to participants aged 50 Years to 89 Years. Per ClinicalTrials.gov, last updated 2021-05-19.

Primary conditionAlzheimer DiseaseRegistry: DementiaReclassifiedWhy we changed it
Registry
Dementia — the first condition term the registry derived for this study.
ClinicalTrials.gg
Alzheimer Disease
Why
  1. The study's listed conditions name Alzheimer Disease, a narrower term within Dementia.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
50 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,942 studies in Alzheimer Disease with a site in United States — 348 open to participants now, 447 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
244th of 1,611
390 · median 73
Started
2008
with 53 others
Phase 3
188 of 1,942
19 open now
Registered
302nd of 1,942
by date

Among the 1,942 studies in Alzheimer Disease with a site in United States, this one is the 244th largest by enrollment of the 1,611 interventional ones that give a count, is one of 54 that started in 2008, is one of 188 in phase 3, and was the 302nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

348 of the 1,942 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

343 more — sign in →

All 348 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,942 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to moderate Alzheimer's disease (AD).

Read the detailed description

Study visits: Each participant will be tested at the investigational site, and if qualified, will be treated intravenously (through a vein) every two weeks for 70 weeks (approximately 18 months). The first three infusions must be done at the site, but if the infusions are well tolerated, subsequent infusions may be done by a qualified healthcare provider in the home or other suitable location. Each participant must return to the site every 3 months for evaluation of cognition as well as blood tests and scans of the brain.

03

Conditions studied

  • Alzheimer´s Disease

Browse trials for

Keywords

  • Alzheimer´s
  • Dementia
  • Dementia of Alzheimer Type
  • Immunoglobulins
  • Gammaglobulins
  • Immune Globulin Intravenous (IGIV)
  • Intravenous Immune Globulin (IVIG)
  • Antibodies
  • Amyloid
  • Immunotherapy
04

In context

Alzheimer Disease Reclassified

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

This study's enrollment of 390 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.

Browse Alzheimer Disease studies →

Lead sponsor

Baxalta now part of Shire is the lead sponsor of 111 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Baxalta became part of Takeda.

Compared within Alzheimer Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Dementia. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Written - participant (or participant´s legally acceptable representative) and caregiver who are willing and able to participate for the duration of the study
  • Diagnosis of probable Alzheimer´s Disease (AD)
  • Dementia of mild to moderate severity defined as (MMSE) 16-26 inclusive at the time of screening
  • Neuroimaging (computed tomography [CT] or MRI) performed after symptom onset consistent with AD diagnosis
  • Ability to comply with testing and infusion regimen, including fluency in English or Spanish, adequate corrected visual acuity and hearing ability
  • On stable doses of regulatory authority approved AD medication(s) for at least 3 months prior to screening. These medications must be continued throughout this study.
  • If receiving psychoactive medications (e.g. antidepressants other than monoamine oxidase inhibitors (MAOIs) and most tricyclics, antipsychotics, anxiolytics, anticonvulsants, mood stabilizers, etc), must be on stable doses for at least 6 weeks prior to screening

Main Exclusion Criteria (Reasons why it might not be appropriate to participate):

  • Any other forms of dementia
  • Medical issues that might increase the risk of treatment with IGIV, 10%, such as:

    1. Significant problems with blood pressure, heart disease, clotting disorders, strokes or recent heart attacks
    2. Evidence of current bleeding in the brain by MRI
    3. Serious problems with the liver or kidneys
    4. Allergies to blood products
  • Medical issues that might interfere with the evaluation of the treatment of dementia or might make dementia worse, such as:

    1. Diabetes
    2. Recent treatment with chemotherapy or immune suppression
    3. The recent use of other drugs, especially antibody therapy for AD
    4. Severe headaches or psychiatric problems
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    IGIV, 10% 400mg/kg

    Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

    Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg

  • Experimental
    IGIV, 10% 200mg/kg

    Immune Globulin Intravenous (Human), 10% (IGIV, 10%)

    Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg

  • Placebo comparator
    Human Albumin 0.25% Solution - 4 mL/kg

    0.25% human albumin solution infused at 4 mL/kg/2weeks

    Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg

  • Placebo comparator
    Human Albumin 0.25% Solution - 2 mL/kg

    0.25% human albumin solution infused at 2 mL/kg/2weeks

    Biological: Placebo solution: Human Albumin 0.25% - 2 mL/kg

Interventions

  • BiologicalImmune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg

    Drug page: Immunoglobulins, Intravenous

    400 mg/kg bodyweight every 2 weeks for 70 weeks

    Also known as: Gammagard Liquid, KIOVIG

  • BiologicalImmune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg

    Drug page: Immunoglobulins, Intravenous

    200 mg/kg bodyweight every 2 weeks for 70 weeks

    Also known as: Gammagard Liquid

  • BiologicalPlacebo solution: Human Albumin 0.25% - 4 mL/kg

    Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks

  • BiologicalPlacebo solution: Human Albumin 0.25% - 2 mL/kg

    Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks

07

What researchers measure

Primary outcomes

  1. Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)

    The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.

    Time frame: Baseline & 18 months

  2. Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

    The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

    Time frame: Baseline & 18 Months

Secondary outcomes

  1. Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)

    The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.

    Time frame: Baseline & 9 months

  2. Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

    The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

    Time frame: Baseline & 9 Months

  3. Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment

    The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse

    Time frame: Baseline & 9 Months

  4. Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment

    The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse

    Time frame: Baseline & 18 Months

  5. Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination

    The 3MS is a comprehensive validated instrument that provides a 100 point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. Scores range from 0 to 100 with lower values indicating greater impairment.

    Time frame: Baseline & 18 months

  6. Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment

    The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.

    Time frame: Baseline & 18 months

  7. Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response

    The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.

    Time frame: Baseline & 18 months

  8. Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response

    The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.

    Time frame: Baseline & 18 months

  9. Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward

    This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.

    Time frame: Baseline & 18 months

  10. Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward

    This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.

    Time frame: Baseline & 18 months

  11. Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency

    In the FAS assessment of phenomic verbal fluency, participants are given 1 minute each to name as many words as they can that begin with a specified letter (F, A, S). To receive credit, words must be verifiable in a dictionary, cannot be proper nouns, and cannot be the same word or variations of the same word (e.g., the same word with a different ending, such as 'acts,' 'acted,' 'acting'). Results are presented as total number correct; therefore, lower numbers indicate greater impairment.

    Time frame: Baseline & 18 months

  12. Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution

    WAIS-R digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.

    Time frame: Baseline & 18 months

  13. Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency

    In this test, which assesses semantic verbal fluency, participants are given 1 minute to name as many items in the category "animals" as possible. To receive credit that word cannot be a mythical animal, but can be an animal species; breed; male, female, or infant name for a species (e.g., bull, cow, calf); in addition, names for birds, fish, reptiles, and insects receive credit. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.

    Time frame: Baseline & 18 months

  14. Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A

    This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,...). Total values for TMT Part A range between 0 and 150 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.

    Time frame: Baseline & 18 months

  15. Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B

    This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,...). Total values for TMT Part B range between 0 and 300 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.

    Time frame: Baseline & 18 months

  16. Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test

    In this test, which assesses constructional ability, visuoperception, and executive functioning, the participant is given a blank sheet of paper and asked to draw the face of a clock showing the numbers and 2 hands set to 'ten after eleven.' Results are presented as score obtained (range 0 to 5, with 0 indicating the greatest impairment).

    Time frame: Baseline & 18 months

  17. Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class

    Time frame: Throughout the study period, approximately 4 years

  18. Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class

    Time frame: Throughout the study period, approximately 4 years

  19. Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class

    Related and unrelated non-SAEs

    Time frame: Throughout the study period, approximately 4 years

  20. Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class

    Related and unrelated SAEs

    Time frame: Throughout the study period, approximately 4 years

  21. Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)

    Refers to non-SAEs and/or SAEs occurring during infusion or within 72 hours of completion of infusion (regardless of causality)

    Time frame: During or within 72 hours of completion of an infusion

  22. Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)

    Each adverse event (AE) that was considered related to investigational product (IP) was linked to the most recent infusion administered

    Time frame: Throughout the study period, approximately 4 years

  23. Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)

    Time frame: Throughout each infusion period

  24. Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits

    Time frame: Throughout the study period, approximately 4 years

  25. Number of Participants Experiencing a Clinically Significant Rash

    Participants requiring systemic therapy or discontinuation from further treatment

    Time frame: Throughout the study period, approximately 4 years

08

Results

Posted Oct 28, 2014

Participant flow

Recruitment was conducted in the U.S., and Canada, at 45 study sites. The first participant was enrolled in December 2008.

Participant flow — Overall Study
MilestoneIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 4 mL/kgPlacebo 2 mL/kg
Started1271355863
Completed1041024947
Not completed2333916
Withdrew: Adverse event51443
Withdrew: Withdrawal by subject5422
Withdrew: Death1300
Withdrew: Physician decision1000
Withdrew: Lost to follow-up0001
Withdrew: Unwilling or unable to participate4624
Withdrew: Protocol violation1100
Withdrew: Requires a prohibited medication1000
Withdrew: Safety risk1101
Withdrew: Study partner unwilling or unable3211
Withdrew: Participant's health declined0001
Withdrew: Caregiver to pursue other treatment0100
Withdrew: Moving out of state0001
Withdrew: Declined move to another study site1000
Withdrew: Change in living situation0001
Withdrew: Study partner decision0001
Withdrew: Admitted to long term nursing care0100

Outcome measures

PrimaryChange From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)

The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.

Time frame:
Baseline & 18 months
Reported as:
Mean · Scores on a scale
Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)7.4 ± 7.958.9 ± 8.208.4 ± 9.37
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.476 · Difference in least-square means: -0.8 · 95% CI -3.1 to 1.5Results combined from 100 imputations from estimates \& standard errors from 100 ANCOVA results for fixed effect of treatment, E4 allele of apolipoprotein E carrier status, \& continuous covariates age at baseline, baseline ADAS-Cog \& education level
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.530 · Difference in least-square means: 0.7 · 95% CI -1.6 to 3.0Results combined from 100 imputations from estimates \& standard errors from 100 ANCOVA results for fixed effect of treatment, E4 allele of apolipoprotein E carrier status, \& continuous covariates age at baseline, baseline ADAS-Cog \& education level
PrimaryChange From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

Time frame:
Baseline & 18 Months
Reported as:
Mean · Scores on a scale
Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)-11.4 ± 10.49-12.4 ± 11.41-11.4 ± 12.19
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.812 · Difference in least-square means: 0.4 · 95% CI -2.9 to 3.7Results combined from 100 imputations from estimates \& standard errors from 100 ANCOVA results for fixed effect of treatment, E4 allele of apolipoprotein E carrier status, \& continuous covariates age at baseline, baseline ADAS-Cog \& education level
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.602 · Difference in least-square means: -0.9 · 95% CI -4.3 to 2.5Results combined from 100 imputations from estimates \& standard errors from 100 ANCOVA results for fixed effect of treatment, E4 allele of apolipoprotein E carrier status, \& continuous covariates age at baseline, baseline ADAS-Cog \& education level
SecondaryChange From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)

The ADAS-Cog is a validated psychometric instrument that evaluates memory (word recall, word recognition), attention, reasoning (following commands), language (naming, comprehension), orientation, ideational praxis (placing letter in envelope) and constructional praxis (copying geometric designs). This test was administered by experienced raters certified by Alzheimer's Disease Cooperative Study (ADCS) at each site. Scores on the ADAS-Cog range from 0-70 with higher scores indicating greater impairment; hence increases from baseline reflect potential cognitive deterioration.

Time frame:
Baseline & 9 months
Reported as:
Mean · Scores on a scale
Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)2.7 ± 5.204.5 ± 6.163.5 ± 6.44
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.368 · Difference in least-square means: -0.7 · 95% CI -2.3 to 0.8Estimated within a ANCOVA model accounting for the fixed effect of treatment, E4 allele of apolipoprotein E carrier status, and for the continuous covariates age at baseline, baseline ADAS-Cog and education level (in years)
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.319 · Difference in least-square means: 0.8 · 95% CI -0.8 to 2.4Estimated within a ANCOVA model accounting for the fixed effect of treatment, E4 allele of apolipoprotein E carrier status, and for the continuous covariates age at baseline, baseline ADAS-Cog and education level (in years)
SecondaryChange From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)

The ADCS-ADL scale is a validated tool to assess instrumental and basic activities of daily living based on a 23 item structured interview of the caregiver or qualified study partner. Scores on the ADCS-ADL range from 0-78 with lower scores indicating greater impairment; hence decreases from baseline reflect potential functional deterioration.

Time frame:
Baseline & 9 Months
Reported as:
Mean · Scores on a scale
Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL)-5.4 ± 7.03-6.1 ± 8.13-5.8 ± 8.32
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.778 · Difference in least-square means: 0.3 · 95% CI -1.8 to 2.4Estimated within a ANCOVA model accounting for the fixed effect of treatment, E4 allele of apolipoprotein E carrier status, and for the continuous covariates age at baseline, baseline ADCS-ADL and education level (in years)
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.851 · Difference in least-square means: -0.2 · 95% CI -2.3 to 1.9Estimated within a ANCOVA model accounting for the fixed effect of treatment, E4 allele of apolipoprotein E carrier status, and for the continuous covariates age at baseline, baseline ADCS-ADL and education level (in years)
SecondaryChange From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment

The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse

Time frame:
Baseline & 9 Months
Reported as:
Number · participants
Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment
participantsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Month 9: Very much better (1)000
Month 9: Much better (2)211
Month 9: A little better (3)737
Month 9: Same (4)333336
Month 9: A little worse (5)525648
Month 9: Much worse (6)191812
Month 9: Very much worse (7)130
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · Mixed Models Analysis · p = 0.306 · Difference in least-square means: 0.1 · 95% CI -0.1 to 0.3
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · Mixed Models Analysis · p = 0.028 · Difference in least-square means: 0.3 · 95% CI 0.0 to 0.5
SecondaryChange From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment

The ADCS-CGIC is a validated categorical measure of change in a participant's clinical condition between baseline and follow-up visits; it is used to assess global clinical status. The ADCS CGIC score is based on direct examination of the participant and an interview of the caregiver. The rater should refer to the baseline ADCS-CGIC worksheets in making a rating. A skilled and experienced clinician who is blinded to treatment assignment rates the participant on a 7-point Likert scale, ranging from 1 (marked improvement) to 7 (marked worsening). 1= Very much better 2= Much better 3= A little better 4= Same 5= A little worse 6= Much worse 7= Very much worse

Time frame:
Baseline & 18 Months
Reported as:
Number · participants
Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment
participantsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Month 18: Very much better (1)000
Month 18: Much better (2)121
Month 18: A little better (3)613
Month 18: Same (4)151516
Month 18: A little worse (5)444336
Month 18: Much worse (6)323332
Month 18: Very much worse (7)774
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · Mixed Models Analysis · p = 0.660 · Difference in least-square means: -0.1 · 95% CI -0.3 to 0.2
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · Mixed Models Analysis · p = 0.766 · Difference in least-square means: 0.0 · 95% CI -0.2 to 0.3
SecondaryChange From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination

The 3MS is a comprehensive validated instrument that provides a 100 point composite rating for spatial and temporal orientation, verbal recall, simple attention, working memory, naming, repetition, comprehension, writing and constructional abilities. Scores range from 0 to 100 with lower values indicating greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · Scores on a scale
Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination-12.1 ± 13.12-15.3 ± 12.76-13.5 ± 10.95
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.206 · Difference in least-square means: 1.9 · 95% CI -1.0 to 4.8
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.331 · Difference in least-square means: -1.4 · 95% CI -4.3 to 1.5
SecondaryChange From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment

The NPI is a validated instrument used to assess behavioral psychopathology in AD; it evaluates the frequency and severity of 12 neuropsychiatric features including delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, sleep and night-time behavior change, and appetite and eating change. The NPI total score ranged 0-144, with higher scores indicating greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · Scores on a scale
Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment3.7 ± 12.934.9 ± 13.302.4 ± 10.77
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.640 · Difference in least-square means: 0.7 · 95% CI -2.1 to 3.4
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.075 · Difference in least-square means: 2.5 · 95% CI -0.3 to 5.3
SecondaryChange From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response

The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.

Time frame:
Baseline & 18 months
Reported as:
Mean · Scores on a scale
Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response-0.5 ± 5.34-0.7 ± 4.40-1.5 ± 5.20
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.093 · Difference in least-square means: 1.1 · 95% CI -0.2 to 2.3
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.094 · Difference in least-square means: 1.1 · 95% CI -0.2 to 2.3
SecondaryChange From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response

The QOL AD is a validated, 13-item instrument developed specifically for individuals with dementia. The assessment rates the participant's quality of life for physical, emotional, interpersonal, and environmental domains. The QOL-AD total score ranged 13-52. Lower scores on the QOL AD are associated with a lower quality of life.

Time frame:
Baseline & 18 months
Reported as:
Mean · Scores on a scale
Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response-3.0 ± 4.97-2.5 ± 5.17-1.6 ± 5.12
Statistical analysis
  • IGIV, 10% 400mg/kg vs IGIV, 10% 200mg/kg · ANCOVA · p = 0.096 · Difference in least-square means: -1.1 · 95% CI -2.3 to 0.2
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.123 · Difference in least-square means: -1.0 · 95% CI -2.2 to 0.3
SecondaryChange From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward

This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · correct responses
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward
correct responsesIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward-0.8 ± 2.00-1.2 ± 2.21-1.1 ± 1.81
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.167 · Difference in least-square means: 0.4 · 95% CI -0.2 to 1.0
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.998 · Difference in least-square means: -0.0 · 95% CI -0.6 to 0.6
SecondaryChange From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward

This test assesses working memory and attention, the rater asks the participant to repeat single-digit number sequences of increasing length, which are read aloud by the rater (in forward or backward order). Two trials are presented for each sequence length, and the test is ended when the participant misses both trials at a given sequence length. The WAIS-R score ranged from 0-14. Results are presented as total number correct; therefore, lower numbers represent greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · correct responses
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward
correct responsesIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward-0.8 ± 1.95-1.2 ± 1.88-1.2 ± 1.79
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.173 · Difference in least-square means: 0.4 · 95% CI -0.2 to 0.9
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.744 · Difference in least-square means: 0.1 · 95% CI -0.4 to 0.6
SecondaryChange From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency

In the FAS assessment of phenomic verbal fluency, participants are given 1 minute each to name as many words as they can that begin with a specified letter (F, A, S). To receive credit, words must be verifiable in a dictionary, cannot be proper nouns, and cannot be the same word or variations of the same word (e.g., the same word with a different ending, such as 'acts,' 'acted,' 'acting'). Results are presented as total number correct; therefore, lower numbers indicate greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · correct responses
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency
correct responsesIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency-4.7 ± 8.60-7.4 ± 9.00-6.3 ± 8.17
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.238 · Difference in least-square means: 1.5 · 95% CI -1.0 to 4.0
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.400 · Difference in least-square means: -1.1 · 95% CI -3.6 to 1.4
SecondaryChange From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution

WAIS-R digit symbol substitution test assesses attention, psychomotor speed, complex scanning, visual tracking, and immediate memory. This test consists of 4 rows each with 25 small blank squares; above each square is a number between 1 and 9. At the top is a 'key,' which pairs each number (1 through 9) with an unfamiliar symbol. The participant has 90 seconds to work as quickly as possible (left to right across the rows) to fill in each blank square with the appropriate symbol based on the number above the square. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · correct responses
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution
correct responsesIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution-6.8 ± 10.61-7.7 ± 9.67-6.2 ± 7.34
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.695 · Difference in least-square means: -0.6 · 95% CI -3.6 to 2.4
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.410 · Difference in least-square means: -1.3 · 95% CI -4.5 to 1.9
SecondaryChange From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency

In this test, which assesses semantic verbal fluency, participants are given 1 minute to name as many items in the category "animals" as possible. To receive credit that word cannot be a mythical animal, but can be an animal species; breed; male, female, or infant name for a species (e.g., bull, cow, calf); in addition, names for birds, fish, reptiles, and insects receive credit. Results are presented as total number correct; therefore, lower numbers indicate greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · correct responses
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency
correct responsesIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency-2.8 ± 4.06-2.2 ± 6.84-2.7 ± 3.82
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.988 · Difference in least-square means: -0.0 · 95% CI -1.5 to 1.5
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.555 · Difference in least-square means: 0.4 · 95% CI -1.0 to 1.9
SecondaryChange From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A

This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,...). Total values for TMT Part A range between 0 and 150 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · seconds
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A
secondsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A21.6 ± 36.9320.5 ± 30.6121.3 ± 35.50
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.783 · Difference in least-square means: -1.5 · 95% CI -12.2 to 9.2
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.700 · Difference in least-square means: -2.1 · 95% CI -13.1 to 8.8
SecondaryChange From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B

This test, which has 2 parts, is used to assess processing speed, visuomotor and perceptual scanning skills, and executive function. In Part A, 25 circles each containing a number between 1 and 25 are randomly placed on a sheet of paper, and the participant is asked to draw a line as quickly as possible between each circle in ascending numerical order. In Part B, 25 circles are again randomly placed on a sheet of paper; however, in this test 13 of the circles contain the numbers 1 through 13, and the remaining 12 circles contain the letters A through L. In this test, the participant must draw a line as quickly as possible between the circles in alternating between numbers and letters in ascending order (e.g., 1 to A, A to 2, 2 to B,...). Total values for TMT Part B range between 0 and 300 seconds. Results are presented as time to complete; therefore, higher numbers indicate greater impairment.

Time frame:
Baseline & 18 months
Reported as:
Mean · seconds
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B
secondsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B13.0 ± 60.4928.4 ± 65.0131.9 ± 66.32
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.191 · Difference in least-square means: -15.2 · 95% CI -38.0 to 7.7
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.892 · Difference in least-square means: -1.6 · 95% CI -25.4 to 22.1
SecondaryChange From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test

In this test, which assesses constructional ability, visuoperception, and executive functioning, the participant is given a blank sheet of paper and asked to draw the face of a clock showing the numbers and 2 hands set to 'ten after eleven.' Results are presented as score obtained (range 0 to 5, with 0 indicating the greatest impairment).

Time frame:
Baseline & 18 months
Reported as:
Mean · Scores on a scale
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test
Scores on a scaleIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test-0.7 ± 1.27-0.7 ± 1.15-0.6 ± 1.17
Statistical analysis
  • IGIV, 10% 400mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.588 · Difference in least-square means: -0.1 · 95% CI -0.4 to 0.2
  • IGIV, 10% 200mg/kg vs Placebo 2 mL/kg or 4 mL/kg · ANCOVA · p = 0.351 · Difference in least-square means: -0.2 · 95% CI -0.5 to 0.2
SecondaryNumber of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class
Time frame:
Throughout the study period, approximately 4 years
Reported as:
Number · participants
Number of Participants Experiencing Study Product-related Non-serious Adverse Events (Non-SAEs), by System Organ Class
participantsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Blood and Lymphatic System Disorders721
Cardiac Disorders104
Eye Disorders110
Gastrointestinal Disorders10137
General Disorders & Administration Site Conditions223213
Immune System Disorders010
Infections and Infestations111
Injury, Poisoning, and Procedural Complications510
Investigations151613
Metabolism and Nutrition Disorders010
Musculoskeletal and Connective Tissue Disorders750
Nervous System Disorders333424
Psychiatric Disorders562
Reproductive System and Breast Disorders010
Respiratory, Thoracic and Mediastinal Disorders344
Skin and Subcutaneous Tissue Disorders26209
Vascular Disorders101817
SecondaryNumber of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class
Time frame:
Throughout the study period, approximately 4 years
Reported as:
Number · participants
Number of Participants Experiencing Study Product-related Serious Adverse Events (SAEs), by System Organ Class
participantsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Cardiac Disorders101
General Disorders & Administration Site Conditions001
Immune System Disorders010
Investigations020
Nervous System Disorders120
Psychiatric Disorders010
Respiratory, Thoracic and Mediastinal Disorders011
Vascular Disorders002
SecondaryNumber of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class

Related and unrelated non-SAEs

Time frame:
Throughout the study period, approximately 4 years
Reported as:
Number · participants
Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class
participantsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Blood and Lymphatic System Disorders1375
Cardiac Disorders31115
Ear and Labyrinth Disorders435
Endocrine Disorders101
Eye Disorders1459
Gastrointestinal Disorders475136
General Disorders & Administration Site Conditions576652
Immune System Disorders173
Infections and Infestations404657
Injury, Poisoning, and Procedural Complications363750
Investigations374830
Metabolism and Nutrition Disorders141516
Musculoskeletal and Connective Tissue Disorders404427
Neoplasms, Benign, Malignant and Unspecified8813
Nervous System Disorders637353
Psychiatric Disorders414949
Renal and Urinary Disorders131612
Reproductive System and Breast Disorders543
Respiratory, Thoracic and Mediastinal Disorders233523
Skin and Subcutaneous Tissue Disorders495231
Social Circumstances010
Surgical and Medical Procedures868
Vascular Disorders223031
SecondaryNumber of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class

Related and unrelated SAEs

Time frame:
Throughout the study period, approximately 4 years
Reported as:
Number · participants
Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class
participantsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Blood and Lymphatic System Disorders201
Cardiac Disorders533
Ear and Labyrinth Disorders100
Gastrointestinal Disorders511
General Disorders & Administration Site Conditions242
Hepatobiliary Disorders011
Immune System Disorders010
Infections and Infestations224
Injury, Poisoning, and Procedural Complications322
Investigations121
Metabolism and Nutrition Disorders112
Musculoskeletal and Connective Tissue Disorders230
Neoplasms, Benign, Malignant and Unspecified033
Nervous System Disorders365
Psychiatric Disorders243
Renal and Urinary Disorders011
Respiratory, Thoracic and Mediastinal Disorders123
Surgical and Medical Procedures011
Vascular Disorders404
SecondaryNumber of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)

Refers to non-SAEs and/or SAEs occurring during infusion or within 72 hours of completion of infusion (regardless of causality)

Time frame:
During or within 72 hours of completion of an infusion
Reported as:
Number · Infusions
Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)
InfusionsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)396467349
SecondaryNumber of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)

Each adverse event (AE) that was considered related to investigational product (IP) was linked to the most recent infusion administered

Time frame:
Throughout the study period, approximately 4 years
Reported as:
Number · Infusions
Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)
InfusionsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs)225265172
SecondaryNumber of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)
Time frame:
Throughout each infusion period
Reported as:
Number · Adverse events
Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)
Adverse eventsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Number of Infusions Discontinued, Slowed, or Interrupted Due to an Adverse Event (AE)482836
SecondaryNumber of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits
Time frame:
Throughout the study period, approximately 4 years
Reported as:
Number · participants
Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits
participantsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Number of Participants Experiencing a Clinically Significant Decrease in Hemoglobin (>1.5 g/dL) Between Consecutive Visits312416
SecondaryNumber of Participants Experiencing a Clinically Significant Rash

Participants requiring systemic therapy or discontinuation from further treatment

Time frame:
Throughout the study period, approximately 4 years
Reported as:
Number · participants
Number of Participants Experiencing a Clinically Significant Rash
participantsIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Rash requiring discontinuation from treatment320
Rash requiring systemic therapy19168

Adverse events

Collected over Throughout the study period of approximately 4 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IGIV, 10% 400mg/kg—21/127 (16.5%)112/127 (88.2%)
IGIV, 10% 200mg/kg—32/135 (23.7%)118/135 (87.4%)
Placebo 2 mL/kg or 4 mL/kg—26/121 (21.5%)103/121 (85.1%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
Urinary Tract InfectionInfections and infestations1/1271/1353/121
Deep Vein ThrombosisVascular disorders1/1270/1353/121
SyncopeNervous system disorders0/1273/1352/121
PyrexiaGeneral disorders0/1270/1352/121
DehydrationMetabolism and nutrition disorders1/1270/1352/121
Lung Neoplasm MalignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1271/1352/121
AgitationPsychiatric disorders1/1270/1352/121
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/1271/1352/121
Microcytic AnaemiaBlood and lymphatic system disorders2/1270/1350/121
Coronary Artery DiseaseCardiac disorders2/1270/1350/121
Most frequent other events
Showing 10 of 37
Most frequent other events
EventIGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 2 mL/kg or 4 mL/kg
HeadacheNervous system disorders29/12734/13522/121
FallInjury, poisoning and procedural complications14/12716/13523/121
Infusion Site ExtravasationGeneral disorders23/12715/13521/121
RashSkin and subcutaneous tissue disorders21/12719/1356/121
DepressionPsychiatric disorders14/12716/13519/121
Blood Pressure IncreasedInvestigations19/12712/1359/121
DiarrhoeaGastrointestinal disorders18/12719/13515/121
HypertensionVascular disorders14/12718/13511/121
NauseaGastrointestinal disorders16/12711/13510/121
DizzinessNervous system disorders16/12713/13512/121

Baseline characteristics

Age, Continuous
Age, Continuous(years)IGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 4 mL/kgPlacebo 2 mL/kgTotal
Mean70.5 ± 9.670.1 ± 8.370.3 ± 9.770.1 ± 10.370.3 ± 9.3
Sex: Female, Male
Sex: Female, Male(Participants)IGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 4 mL/kgPlacebo 2 mL/kgTotal
Female69743333209
Male58612530174
Region of Enrollment
Region of Enrollment(Participants)IGIV, 10% 400mg/kgIGIV, 10% 200mg/kgPlacebo 4 mL/kgPlacebo 2 mL/kgTotal
United States1171275658358
Canada1082525
09

Study locations

41 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Sun City, Arizona, United States
  • Tucson, Arizona, United States
  • Irvine, California, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • National City, California, United States
  • Orange, California, United States
  • New Haven, Connecticut, United States
  • Washington, District of Columbia, United States
  • Miami Beach, Florida, United States
  • Sarasota, Florida, United States
  • Tampa, Florida, United States
  • Chicago, Illinois, United States
  • Iowa City, Iowa, United States
  • Kansas City, Kansas, United States
  • Lexington, Kentucky, United States
  • Burlington, Massachusetts, United States
  • Paw Paw, Michigan, United States
  • Rochester, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Las Vegas, Nevada, United States
  • Liverpool, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Cleveland, Ohio, United States
  • Tulsa, Oklahoma, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • North Charleston, South Carolina, United States
  • Franklin, Tennessee, United States
  • Dallas, Texas, United States
  • Salt Lake City, Utah, United States
  • Madison, Wisconsin, United States
  • Vancouver, British Columbia, Canada
  • London, Ontario, Canada
  • Toronto, Ontario, Canada
  • Montreal, Quebec, Canada
10

References and documents

Publications

  • Relkin N, Gessert D, Stokes K, Adamiak B, Ngo LY, Thomas R, Gelmont D, Aisen P. The Gammaglobulin Alzheimer Partnership Study (GAP): Design, screening, enrollment and futility analysis results. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 8[4 Suppl], P456. 2012.
  • Ngo L, Adamiak B, Gelmont D. A confirmatory phase 3 randomized, double-blind, placebo-controlled study of the safety and effectiveness of immune globulin intravenous (human), 10% solution (Gammagard Liquid/Kiovig) for the treatment of mild to moderate Alzheimer's Disease. Poster Presentation: Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), Paris, France July 16-21 2011.
  • Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS; Alzheimer's Disease Cooperative Study. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 2017 May 2;88(18):1768-1775. doi: 10.1212/WNL.0000000000003904. Epub 2017 Apr 5. PubMed 28381506 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Dec 2012, 47 months.

Results were first posted in Oct 2014, 1 year 10 months after primary completion.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 47 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2009
First posted
Jan 8, 2009
StartActual
Dec 19, 2008
Primary completionActual
Dec 10, 2012
CompletionActual
Dec 10, 2012
Results first posted
Oct 28, 2014
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00818662
Collaborators
Alzheimer's Disease Cooperative Study (ADCS)
Responsible party
Sponsor
First posted
Jan 8, 2009
Start date
Dec 19, 2008
Primary completion
Dec 10, 2012
Completion
Dec 10, 2012
Results posted
Oct 28, 2014
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion